title: A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?
abstract: The most widely prescribed oral anti-diabetic agent today in the world today is a member of the biguanide class of drugs called metformin. Apart from its use in diabetes, it is currently being investigated for its potential use in many diseases such as cancer, cardiovascular diseases, Alzheimer's disease, obesity, comorbidities of diabetes such as retinopathy, nephropathy to name a few. Numerous in-vitro and in-vivo studies as well as clinical trials have been and are being conducted with a vast amount of literature being published every day. Numerous mechanisms for this drug have been proposed, but they have been unable to explain all the actions observed clinically. It is of interest that insulin has a stimulatory effect on cellular growth. Metformin sensitizes the insulin action but believed to be beneficial in cancer. Like -wise metformin is shown to have beneficial effects in opposite sets of pathological scenario looking from insulin sensitization point of view. This requires a comprehensive review of the disease conditions which are claimed to be affected by metformin therapy. Such a comprehensive review is presently lacking. In this review, we begin by examining the history of metformin before it became the most popular anti-diabetic medication today followed by a review of its relevant molecular mechanisms and important clinical trials in all areas where metformin has been studied and investigated till today. We also review novel mechanistic insight in metformin action in relation to microbiome and elaborate implications of such aspect in various disease states. Finally, we highlight the quandaries and suggest potential solutions which will help the researchers and physicians to channel their research and put this drug to better use.
authors.affiliation: Department of Pharmacology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
authors.forename: Kunal
authors.initials: K
authors.lastname: Maniar
authors.affiliation: Department of Pharmacology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
authors.forename: Amal
authors.initials: A
authors.lastname: Moideen
authors.affiliation: Department of Experimental Medicine & Biotechnology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
authors.forename: Ankur
authors.initials: A
authors.lastname: Mittal
authors.affiliation: Department of Pharmacology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
authors.forename: Amol
authors.initials: A
authors.lastname: Patil
authors.affiliation: Department of Pharmacology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
authors.forename: Amitava
authors.initials: A
authors.lastname: Chakrabarti
authors.affiliation: Department of Experimental Medicine & Biotechnology, Post Graduate Institute of Medical Education & Research, Chandigarh, India. Electronic address: dibyajyoti5200@yahoo.co.in.
authors.forename: Dibyajyoti
authors.initials: D
authors.lastname: Banerjee
mesh_terms: D000818:Animals; D002087:Butyrates / Q000494:pharmacology* / Q000627:therapeutic use*; D004357:Drug Synergism; D000069196:Gastrointestinal Microbiome / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D008687:Metformin / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D002087:Butyrates; D007004:Hypoglycemic Agents; D008687:Metformin
keywords: Antibiotics; Diabetes mellitus; Insulin; Metformin; NAFLD